spacer
Product Overview

Overview

Waban’s products have been built based on consolidated input from our customer base across the Life Sciences industry. All products provide respective regulatory (21 CFR Part 11, GLP & HIPAA) compliance. Our products include:

Clinical Data Analysis Systems

Waban Explorer - Integrate & Explore Data from Multiple Sources
Waban Explorer is a comprehensive system to capture, manage, share and analyze, in an integrated fashion, the vast amount of data being generated in the drug discovery and development processes. more  »

Waban CDR  - A Metadata-Driven Controlled Clinical Data Repository (CDR)
Waban CDR provides a secure 21 CFR Part 11 compliant version controlled data repository for storing and managing clinical trials data (both data and metadata). more  »

Waban SCE  - Manage Your Data, Analysis & Reporting
Waban SCE for Clinical Biostatistics provides a secure, 21 CFR Part 11 compliant, controlled statistical computing environment (SCE) where routine and repetitious statistical programming and analysis jobs can be automated and tracked. more  »

Laboratory Information & Clinical Specimen Management Systems

Waban LIMS - A Comprehnesive System for Biomarkers and Pharmacogenomics
Waban LIMS is a laboratory information management system that supports clinical genotyping, sequencing, expression, microarrays, Affymetrix®, pre-clinical, clinical pathology, and other pharmacogenomics and biomarkers related processes.  
more  »

Waban SMS - Overcome Workflows & Processes in Specimen Management
Waban Specimen Management System is a comprehensive system designed to meet the complex workflows and processes involved in handling, receiving, shipping, and storage of samples collected for use in clinical trials and for biobanking. more  »

Drug Safety

Waban DSS - Track & Manage Adverse Events
Waban Drug Safety Systems provide researchers with an analytic data repository and associated tools required to maintain a drug safety database to assess safety of compounds that are already in the market and those in the drug-development pipeline. more  »

Top

 print this page  Email us